405171-01-9

Basic information

• Product Name: 2(1H)-Quinolinone, 4-hydroxy-3-[5-(4-morpholinyl)-1H-benzimidazol-2-yl]-1-(phenylmethyl)-
• CAS NO: 405171-01-9
• Molecular Formula: C27H24N4O3
• Molecular Weight: 452.513
• Mol File: 405171-01-9.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 2(1H)-Quinolinone, 4-hydroxy-3-[5-(4-morpholinyl)-1H-benzimidazol-2-yl]-1-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinolinone, 4-hydroxy-3-[5-(4-morpholinyl)-1H-benzimidazol-2-yl]-1-(phenylmethyl)-(405171-01-9)
• EPA Substance Registry System: 2(1H)-Quinolinone, 4-hydroxy-3-[5-(4-morpholinyl)-1H-benzimidazol-2-yl]-1-(phenylmethyl)-(405171-01-9)

Safety Data

• Hazardous Substances Data: 405171-01-9(Hazardous Substances Data)

Usage

Molecular structure

The compound has a complex molecular structure that includes a quinolinone ring system and a benzimidazole group.

Substituents

The compound contains a morpholine substituent and a phenylmethyl group.

Biological activity

The compound is known to have biological activities, which means it may have an effect on living organisms.

Pharmaceutical applications

Due to its biological activity, the compound may have potential pharmaceutical applications.

Handling precautions

The compound should be handled with caution due to its complex structure and potential reactivity.

Upstream product

• 402948-33-8 ethyl 2-(5-morpholin-4-ylbenzimidazol-2-yl)acetate 

Downstream Products

• 405171-06-4 4-chloro-3-(5-morpholin-4-ylbenzimidazol-2-yl)-1-benzylhydroquinolin-2-one 

Relevant articles and documents

BENZIMIDAZOLE QUINOLINONES AND USES THEREOF

Methods of inhibiting various enzymes and treating various conditions are provided that include administering to a subject a compound of Structure I or IB, a pharmaceutically acceptable salt thereof, a tautomer thereof, or a pharmaceutically acceptable salt of the tautomer. Compounds having the Structure I and IB have the following structures and have the variables described herein. Such compounds may be used to prepare medicaments for use in inhibiting various enzymes and for use in treating conditions mediated by such enzymes.

Quinolinone derivatives

Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.